Test Price
2,800 AED✅ Home Collection Available
SERPINA1 Gene (Alpha-1 Antitrypsin Deficiency) Genetic Test in UAE | 2800 AED | DHA Guidelines
Executive Summary & Core Metrics
Clinical Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Laboratory (Cert: INT/EGQ/2509DA/3139). Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all Emirates. Post-Test Clinical Guidance: Complimentary telephonic interpretation session with a DHA-licensed molecular geneticist to explain your results in clinical context. Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The SERPINA1 gene encodes alpha-1 antitrypsin (AAT), a critical protease inhibitor protecting lung and liver tissue. This next‑generation sequencing test sequences the entire coding region and splice sites to detect pathogenic variants causing alpha‑1 antitrypsin deficiency (AATD), a hereditary condition associated with early‑onset emphysema and chronic liver disease. Ideal for symptomatic patients, family screening, and pre‑conception risk assessment.
| Feature | Our Test (NGS) | Conventional Genotyping |
|---|---|---|
| Detection Scope | >99% of clinically relevant variants (coding + splice) | Limited to common Pi*S & Pi*Z alleles only |
| Diagnostic Sensitivity | 99.9% | ~70% for rare/null alleles |
| Turnaround Time | 3–4 weeks | 1–2 weeks |
| Sample | Whole Blood / FTA Card / Extracted DNA | Whole Blood only |
Physician Insight & Safety Protocols
“Next‑generation sequencing of the SERPINA1 gene provides unparalleled detection of pathogenic variants, including rare and null alleles. Interpretation of results must always be combined with serum biomarkers and family history. Genetic counseling is strongly advised for all individuals considering this test.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID: 9294403
Medication Safety Advisory
Do not discontinue prescribed medication (e.g., bronchodilators, ursodeoxycholic acid) without consulting your treating physician. Genetic findings guide risk but never replace ongoing symptom management.
Exclusion Criteria & Emergency Red Flags
- Inability to provide a blood or DNA sample due to severe coagulopathy (uncorrected INR >3.0).
- Active febrile illness requiring urgent clinical attention—defer test until stable.
- Minors without legal guardian consent (as per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Seek immediate emergency care if you experience sudden severe shortness of breath, jaundice with confusion, or massive ascites—these are not related to sample collection but may signal decompensated AATD liver or lung disease.
Patient FAQ & Clinical Guidance
1. What does the SERPINA1 genetic test detect, and how does it work?
This test uses next‑generation sequencing to identify DNA variants in the entire SERPINA1 coding region and flanking splice sites, delivering a comprehensive assessment of alpha‑1 antitrypsin deficiency risk.
2. Do I need to stop any medications or supplements before the sample collection?
No medication adjustment is required; this is a DNA-based test unaffected by drugs, diet, or supplements—simply provide a blood or FTA card sample at your convenience.
3. How should I interpret a “variant of uncertain significance” (VUS) result?
A VUS does not confirm disease and must be interpreted with family history and serum AAT levels—our DHA‑licensed genetic counsellors explain all findings during a dedicated post‑test call.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed solely for diagnostic purposes in accordance with DHA regulatory requirements. Your data never leaves UAE jurisdiction without explicit consent.
Clinical & Logistical Metadata
| Test Name | SERPINA1 Gene (Alpha-1 Antitrypsin Deficiency) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood, FTA Card, or Extracted DNA |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | E88.01 (Alpha-1-antitrypsin deficiency) |
| LOINC Code | 81247-8 (SERPINA1 gene full sequencing) |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians